Edit RNA Processing Development Innovative RNA Drug Synth completes $81 million round of A financing

Traditional drug research and development by regulating the activity of disease-related proteins or enzymes to treat diseases, however, it is estimated that only 10% of proteins in the human body can be regulated by small molecules, 10% of proteins can be regulated by biomoglytes on the cell surface, and up to 80% of proteins can not be regulated with existing drugs, is considered "non-drugable".
as an intermediate of genetic information that connects DNA and proteins, RNA is now considered a key molecule involved in almost all biological pathways.
when researchers found RNA diversity, they also noted the advantages of using RNA as a therapeutic molecule.
RNA therapy is more flexible than traditional therapies and can cope with a variety of diseases in different ways.
pharmaceutical companies are also exploring the possibility of using RNA as an innovative therapy in different ways: among them, direct use of RNA molecules as innovative therapies, such as RNAi therapy Oxlumo (lumasiran), which was just approved by Allenlam Pharmaceuticals last month;
Remix has adopted a new strategy to treat diseases by reprogramming the RNA process.
as an intermediate step in transcription and translation, RNA transcription molecules can be regulated in a variety of ways.
Remix has developed the company's technology platform, REMaster, over the past year, providing the basis for better drug development.
According to the press release, the platform consists of three parts: a database of potential target drugs consisting of mRNA molecular transcription groups, a screening technique to validate genetic targets or to identify and optimize chemical maps, and a company-specific library of compounds that can serve as a starting point for drug discovery.
Remix is designing drugs that target RNA processing to regulate the process by which RNA sequences are produced.
small molecule drugs designed by the company can be therapeutically regulated throughout the body, with the potential to treat a variety of diseases, including cancer, central system diseases, rare diseases and so on.
Remix treats diseases by targeting RNA processes (Photo: Remix's official website) Reference: s1 remix Therapeutics debuts with $81M to 'reprogram' disease-causing RNA. Retrieved December 9, 2020, from [2] Remix Therapeutics Launches with $81 Million Financing to Develop Small Molecule Therapies Designed to Reprogram RNA Processing. Retrieved December 9, 2020, from。